Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_curated type ECO_0000205 NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- source_evidence_curated label "DisGeNET evidence - CURATED" NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- source_evidence_curated comment "Gene-disease associations manually curated." NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_assertion description "[Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_assertion evidence source_evidence_curated NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_assertion SIO_000772 16763187 NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_assertion wasDerivedFrom ctd_human-20130708 NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_assertion wasGeneratedBy ECO_0000218 NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.
- ctd_human-20130708 importedOn "2013-07-24" NP26191.RATIi6DeHp9e91Xp8eXkPB-NOuD1xVCuRnkC_0wDV7q6g130_provenance.